Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy shows promise as First-Line attack on tough lung cancer

NCT ID NCT03003962

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a drug called durvalumab (an immunotherapy that helps the immune system fight cancer) to standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer, no specific gene mutations, and good physical health took part. The main goal was to see if durvalumab helps people live longer than chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

669 people

The number who actually took part.

Started

Jan 2017

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Aged at least 18 years * Documented evidence of Stage IV NSCLC * No sensitizing EGFR mutation and ALK rearrangement * PD-L1 high expression * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * Prior chemotherapy or any other systemic therapy for advanced NSCLC * Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines * Brain metastases or spinal cord compression unless the patient is stable and off steroids for at least 14 days prior to start of study treatment * Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant * Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease\]

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung carcinoma (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung carcinoma (NSCLC)

Contacts and locations

Locations

  • Research Site

    Anaheim, California, 92801, United States

  • Research Site

    Box Hill, 3128, Australia

  • Research Site

    Gosford, 2250, Australia

  • Research Site

    Kogarah, 2217, Australia

  • Research Site

    St Leonards, 2065, Australia

  • Research Site

    Beijing, 100032, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Beijing, 100853, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changchun, 130000, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chongqing, 400030, China

  • Research Site

    Guangzhou, 510080, China

  • Research Site

    Guangzhou, 510095, China

  • Research Site

    Haikou, 570311, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310006, China

  • Research Site

    Hangzhou, 310009, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Jinan, 250031, China

  • Research Site

    Linhai, 317000, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Ningbo, 315010, China

  • Research Site

    Shanghai, 200030, China

  • Research Site

    Shenyang, 110042, China

  • Research Site

    Shijiazhuang, 050020, China

  • Research Site

    Ürümqi, 830000, China

  • Research Site

    Ürümqi, 830054, China

  • Research Site

    Wanzhou, 404000, China

  • Research Site

    Wenzhou, CN-325000, China

  • Research Site

    Wuhan, 430010, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Xi'an, 710038, China

  • Research Site

    Xi'an, 710061, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Zhuhai, 519099, China

  • Research Site

    Budapest, 1083, Hungary

  • Research Site

    Budapest, 1121, Hungary

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Deszk, 6772, Hungary

  • Research Site

    Farkasgyepü, 8582, Hungary

  • Research Site

    Gyöngyös - Mátraháza, 3200, Hungary

  • Research Site

    Székesfehérvár, 8000, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Almelo, 7600SZ, Netherlands

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Grudziądz, 86-300, Poland

  • Research Site

    Koszalin, 75-581, Poland

  • Research Site

    Lublin, 20-090, Poland

  • Research Site

    Mrozy, 05-320, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Wroclaw, 53-413, Poland

  • Research Site

    Arkhangelsk, 163045, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Novosibirsk, 630108, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Rostov-on-Don, 344037, Russia

  • Research Site

    Saint Petersburg, 194291, Russia

  • Research Site

    Saint Petersburg, 196603, Russia

  • Research Site

    Saint Petersburg, 197183, Russia

  • Research Site

    Saint Petersburg, 197342, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Volgograd, 400138, Russia

  • Research Site

    Changwon-si, 51353, South Korea

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Daegu, 42415, South Korea

  • Research Site

    Incheon, 21565, South Korea

  • Research Site

    Jinju, 660-702, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Suwon, 16499, South Korea

  • Research Site

    Taichung, 402, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Muang, 50200, Thailand

  • Research Site

    Songkhla, 90110, Thailand

  • Research Site

    Ankara, 06490, Turkey (Türkiye)

  • Research Site

    Istanbul, 34030, Turkey (Türkiye)

  • Research Site

    Istanbul, 34854, Turkey (Türkiye)

  • Research Site

    Malatya, 44100, Turkey (Türkiye)

  • Research Site

    Pamukkale, 20070, Turkey (Türkiye)

  • Research Site

    Can Tho, 900000, Vietnam

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hanoi, 10000, Vietnam

  • Research Site

    Ho Chi Minh City, 10000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

  • Research Site

    Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.